[go: up one dir, main page]

UY23697A1 - Procedimiento para la preparacion de 5'-deoxi-5'-fluorcitidinas sustitutas del n-oxicarbonilo - Google Patents

Procedimiento para la preparacion de 5'-deoxi-5'-fluorcitidinas sustitutas del n-oxicarbonilo

Info

Publication number
UY23697A1
UY23697A1 UY23697A UY23697A UY23697A1 UY 23697 A1 UY23697 A1 UY 23697A1 UY 23697 A UY23697 A UY 23697A UY 23697 A UY23697 A UY 23697A UY 23697 A1 UY23697 A1 UY 23697A1
Authority
UY
Uruguay
Prior art keywords
deoxy
compound
radical
oxycarbonyl
fluorcitidines
Prior art date
Application number
UY23697A
Other languages
English (en)
Inventor
Motohiro Arasaki
Hideo Ishitsuka
Isami Kuruma
Masanori Miwa
Chikako Murasaki
Nobuo Shimma
Isao Umeda
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8210304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY23697(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of UY23697A1 publication Critical patent/UY23697A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere al procedimiento para preparar un compuesto de fórmula general (I) (ver figura 1) derivados de N4-(oxicarbonil sustituidos)-5'-desoxi-5-fuorocitidina, así como también hidratos o solvatos de dichos compuestos, donde: R1 es un radical hidrocarburo saturado o insaturado; R2 es un átomo de hidrógeno o un radical fácilmente hidrolizable en condiciones fisiológicas. El procedimiento comprende la reacción de un compuesto de fórmula general (II) (figura 2), donde R4 es un radical de protección de los hidroxilos con un compuesto: R1OCOC1, y si es necesario se eliminan los radicales de protección. Ejemplo no limitante: 5'-desoxi-5-fluoro-N4-[(1,1,2-trimetilpropoxi)carbonil]citidina. Los productos según la invención son de utilidad para el tratamiento de tumores.
UY23697A 1992-12-18 1993-12-17 Procedimiento para la preparacion de 5'-deoxi-5'-fluorcitidinas sustitutas del n-oxicarbonilo UY23697A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP92121538 1992-12-18

Publications (1)

Publication Number Publication Date
UY23697A1 true UY23697A1 (es) 1994-06-08

Family

ID=8210304

Family Applications (1)

Application Number Title Priority Date Filing Date
UY23697A UY23697A1 (es) 1992-12-18 1993-12-17 Procedimiento para la preparacion de 5'-deoxi-5'-fluorcitidinas sustitutas del n-oxicarbonilo

Country Status (40)

Country Link
US (1) US5472949A (es)
EP (1) EP0602454B1 (es)
JP (1) JP2501297B2 (es)
KR (1) KR100347218B1 (es)
CN (1) CN1035617C (es)
AT (1) ATE137244T1 (es)
AU (1) AU671491B2 (es)
BG (1) BG61485B1 (es)
BR (1) BR9305089A (es)
CA (1) CA2103324C (es)
CZ (1) CZ284788B6 (es)
DE (1) DE69302360T2 (es)
DK (1) DK0602454T3 (es)
EE (1) EE03086B1 (es)
ES (1) ES2086856T3 (es)
FI (1) FI112365B (es)
GE (1) GEP20074251B (es)
GR (1) GR3020286T3 (es)
HR (1) HRP931430B1 (es)
HU (2) HU218291B (es)
IL (1) IL108000A0 (es)
IS (1) IS4108A (es)
LT (1) LT3115B (es)
LV (1) LV10625B (es)
MY (1) MY109282A (es)
NO (1) NO300066B1 (es)
NZ (1) NZ250414A (es)
PH (1) PH30168A (es)
PL (1) PL174100B1 (es)
RO (1) RO112619B1 (es)
RU (2) RU2458932C2 (es)
SA (1) SA93140409B1 (es)
SI (1) SI9300648B (es)
SK (1) SK281403B6 (es)
SV (1) SV1993000080A (es)
TW (1) TW372239B (es)
UA (1) UA39158C2 (es)
UY (1) UY23697A1 (es)
YU (1) YU49411B (es)
ZA (1) ZA939293B (es)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476932A (en) * 1994-08-26 1995-12-19 Hoffmann-La Roche Inc. Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
EP0882734B1 (en) * 1997-06-02 2009-08-26 F. Hoffmann-La Roche Ag 5'-Deoxy-cytidine derivatives
NZ330360A (en) * 1997-06-02 1999-03-29 Hoffmann La Roche 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
US6005098A (en) * 1998-02-06 1999-12-21 Hoffmann-La Roche Inc. 5'deoxycytidine derivatives
ID30046A (id) * 1998-09-25 2001-11-01 Warner Lambert Co Kemoterapi kanker dengan asetildinalina digabung dengan gemsitabina, kapestabina atau kisplatin
US20070122481A1 (en) * 1998-11-02 2007-05-31 Elan Corporation Plc Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
EE200200471A (et) 2000-02-28 2003-12-15 Aventis Pharma S.A. Farmatseutiline kompositsioon, mis sisaldab kamptotetsiini või selle derivaati kombinatsioonis pürimidiini derivaadiga ning on ette nähtud vähktõve raviks
WO2001076581A1 (en) * 2000-04-11 2001-10-18 Sayuri Yamada Curcumin compositions
KR100631754B1 (ko) * 2000-08-09 2006-10-09 주식회사 코오롱 Ｎ-알킬옥시카르보닐-5-플루오로사이토신 유도체 및 그의제조방법
KR100730768B1 (ko) * 2000-08-09 2007-06-21 코오롱생명과학 주식회사 5'-데옥시-ｎ-알킬옥시카르보닐-5-플루오로사이토신-5'-카르복실산 및 그 유도체와 이들의 제조방법
GB0113374D0 (en) * 2001-06-04 2001-07-25 Jerram Clare Washing line umbrella
WO2003057217A1 (en) * 2002-01-14 2003-07-17 Novartis Ag Combinations comprising epothilones and anti-metabolites
AU2003217676B2 (en) 2002-02-22 2009-06-11 Takeda Pharmaceutical Company Limited Active agent delivery systems and methods for protecting and administering active agents
BR0316238A (pt) * 2002-11-15 2005-10-11 Warner Lambert Co Quimioterapia de associação compreendendo um inibidor de mek e capecitabina para tratamento de câncer
US20080026044A1 (en) * 2003-05-20 2008-01-31 Jonathan Lewis Combination Chemotherapy Comprising Capecitabine and a Liposomal Platinum Complex
DK1689404T3 (da) * 2003-11-13 2009-01-26 Pharma Mar Sau Kombination af et-743 med 5-fluoracil-prodrugs til behandling af cancer
ES2310298T3 (es) * 2003-12-22 2009-01-01 F. Hoffmann-La Roche Ag Proceso para producir derivados de fluorocitidina.
CN113952338A (zh) 2005-02-03 2022-01-21 综合医院公司 治疗吉非替尼耐药性癌症的方法
AU2006228581A1 (en) * 2005-04-01 2006-10-05 F. Hoffmann-La Roche Ag Method for administration of capecitabine
NZ587586A (en) 2005-07-18 2012-04-27 Bipar Sciences Inc Treatment of cancer
US20080292729A1 (en) 2005-07-21 2008-11-27 Nuvo Research Inc. Stabilized Chlorite Solutions in Combination with Fluoropyrimidines for Cancer Treatment
CN103110948A (zh) 2005-11-04 2013-05-22 惠氏公司 mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
EP3838903B1 (en) 2005-12-13 2023-11-22 Incyte Holdings Corporation Pyrrolo[2,3-d]pyrimidine derivative as janus kinase inhibitor
US20100160442A1 (en) * 2006-07-18 2010-06-24 Ossovskaya Valeria S Formulations for cancer treatment
US20080085310A1 (en) * 2006-10-06 2008-04-10 Maria Oksana Bachynsky Capecitabine rapidly disintegrating tablets
CN100425617C (zh) * 2006-10-31 2008-10-15 浙江海正药业股份有限公司 一种含氟嘧啶类化合物烷氧羰酰化的方法
ITMI20070435A1 (it) 2007-03-05 2008-09-06 Innovate Biotechnology Srl 2',3'-di-o-acil-5-fluoronucleosidi
BRPI0810067A2 (pt) * 2007-04-20 2014-10-21 Reddys Lab Ltd Dr Processo para a preparação de capecitabina
EP2164856A1 (en) * 2007-06-01 2010-03-24 Synthon B.V. Processes related to making capecitabine
CN101932582B (zh) 2007-06-13 2013-09-25 因塞特公司 詹纳斯激酶抑制剂(R)-3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的盐
US7842675B2 (en) * 2007-09-15 2010-11-30 Protia, Llc Deuterium-enriched capecitabine
WO2009042064A2 (en) * 2007-09-21 2009-04-02 Nektar Therapeutics Al, Corporation Oligomer-nucleoside phosphate conjugates
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
KR101013312B1 (ko) * 2007-11-19 2011-02-09 한미홀딩스 주식회사 카페시타빈의 제조방법 및 이에 사용되는 β-아노머가강화된 트리알킬카보네이트 화합물의 제조방법
AR064165A1 (es) 2007-12-06 2009-03-18 Richmond Sa Com Ind Y Financie Un procedimiento para la preparacion de capecitabina e intermediarios utilizables en dicho procedimiento
KR20090122955A (ko) * 2008-01-03 2009-12-01 플러스 케미칼스, 에스.에이. 카페시타빈의 제조 방법
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
EP3135285B1 (en) 2008-06-17 2018-08-15 Wyeth LLC Antineoplastic combinations containing hki-272 and vinorelbine
CN105963313A (zh) 2008-08-04 2016-09-28 惠氏有限责任公司 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
WO2010065586A2 (en) * 2008-12-02 2010-06-10 Dr. Reddy's Laboratories Ltd. Preparation of capecitabine
US8603999B2 (en) 2008-12-05 2013-12-10 Commonwealth Scientific And Industrial Research Organisation Amphiphile prodrugs
KR20190128004A (ko) 2009-04-06 2019-11-13 와이어쓰 엘엘씨 네라티닙을 이용한 유방암의 치료법
FR2945211A1 (fr) 2009-05-06 2010-11-12 Sanofi Aventis Combinaison antitumorale comprenant la cabazitaxel et la capecitabine
RS59632B1 (sr) 2009-05-22 2020-01-31 Incyte Holdings Corp 3-[4-(7h-pirolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]oktan- ili heptan-nitril kao jak inhibitori
US20110021769A1 (en) * 2009-07-23 2011-01-27 Scinopharm Taiwan Ltd. Process for Producing Fluorocytidine Derivatives
WO2011067588A1 (en) 2009-12-04 2011-06-09 Generics [Uk] Limited Cyclic sulphinyl esters of cytidine
WO2011104540A1 (en) * 2010-02-24 2011-09-01 Generics [Uk] Limited One step process for the preparation of capecitabine
ME02386B (me) 2010-03-10 2016-09-20 Incyte Holdings Corp Derivati piperidin-4-il azetidina kao inhibitori jak1
ES2584433T3 (es) 2010-03-12 2016-09-27 Genzyme Corporation Terapia de combinación para tratar cáncer de mama
NZ603686A (en) 2010-05-21 2014-11-28 Incyte Corp Topical formulation for a jak inhibitor
CN102260309B (zh) * 2010-05-24 2014-10-22 重庆福安药业(集团)股份有限公司 一种高纯度卡培他滨的制备方法
TW201249845A (en) 2010-11-19 2012-12-16 Incyte Corp Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
CN102558262A (zh) * 2010-12-23 2012-07-11 天津泰普药品科技发展有限公司 一种高纯度卡培他滨的制备方法
KR20140040819A (ko) 2011-06-20 2014-04-03 인사이트 코포레이션 Ｊａｋ 저해제로서의 아제티디닐 페닐, 피리딜 또는 피라지닐 카르복스아미드 유도체
CN102266303A (zh) * 2011-07-07 2011-12-07 程雪翔 一种卡培他滨药用组合物及其制备方法
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
CN102516338B (zh) * 2011-12-09 2014-04-02 海南锦瑞制药股份有限公司 一种卡培他滨化合物、其药物组合物及其制备方法
TWI560195B (en) * 2012-01-13 2016-12-01 Pharmaessentia Corp Novel synthesis of 5-deoxy-5'-fluorocytidine compounds
US10166191B2 (en) 2012-11-15 2019-01-01 Incyte Corporation Sustained-release dosage forms of ruxolitinib
DK2964650T3 (en) 2013-03-06 2019-02-11 Incyte Holdings Corp PROCEDURES AND INTERMEDIATES FOR THE MANUFACTURE OF A JAK INHIBITOR
SI3030227T1 (sl) 2013-08-07 2020-08-31 Incyte Corporation Dozirne oblike s podaljšanim sproščanjem za inhibitor JAK1
AR097388A1 (es) * 2013-08-20 2016-03-09 Incyte Corp Beneficio de supervivencia en pacientes con tumores sólidos con niveles elevados de proteína c reactiva
EP2883959A1 (en) 2013-12-13 2015-06-17 Plasmia Biotech, S.L. Enzymatic production of cytosinic nucleoside analogues
CN103897006A (zh) * 2013-12-18 2014-07-02 吉林修正药业新药开发有限公司 一种卡培他滨异构体的制备方法
WO2015191563A1 (en) 2014-06-09 2015-12-17 Lipomedix Pharmaceuticals Ltd. Combination chemotherapy comprising a liposomal prodrug of mitomycin c
CN104530164A (zh) * 2014-12-31 2015-04-22 辰欣药业股份有限公司 一种卡培他滨的合成工艺
KR20160117060A (ko) 2015-03-31 2016-10-10 이승주 유아용 탁자
CN105646625B (zh) * 2015-12-29 2019-06-11 江苏吴中医药集团有限公司 一种卡培他滨的制备方法
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
EP3565549B1 (en) 2017-01-09 2022-03-09 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
TR201702500A2 (tr) * 2017-02-20 2017-07-21 Anadolu Ueniversitesi Serani̇b-2?ni̇n akci̇ğer kanseri̇ ve meme kanseri̇ni̇n tedavi̇si̇nde kullanimi
US10435429B2 (en) 2017-10-03 2019-10-08 Nucorion Pharmaceuticals, Inc. 5-fluorouridine monophosphate cyclic triester compounds
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
EP3737376B1 (en) 2018-01-09 2024-04-17 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human diseases
AU2019207626B2 (en) 2018-01-10 2023-10-05 Nucorion Pharmaceuticals, Inc. Phosphor(n)amidatacetal and phosph(on)atalcetal compounds
US11427550B2 (en) 2018-01-19 2022-08-30 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
CN111801339B (zh) * 2018-01-19 2025-06-24 纽科利制药公司 5-氟尿嘧啶化合物
LT3746429T (lt) 2018-01-30 2022-05-10 Incyte Corporation (1-(3-fluor-2-(trifluormetil)izonikotinil)piperidin-4-ono) gamybos būdai
MY206999A (en) 2018-03-30 2025-01-23 Incyte Corp Treatment of hidradenitis suppurativa using jak inhibitors
AU2020207026A1 (en) 2019-01-11 2021-07-29 Lipomedix Pharmaceuticals Ltd. Liposome composition comprising liposomal prodrug of mitomycin C and method of manufacture
CA3143349A1 (en) 2019-07-17 2021-01-21 Nucorion Pharmaceuticals, Inc. Cyclic deoxyribonucleotide compounds
CN115605492B (zh) 2020-04-21 2025-09-16 配体制药股份有限公司 核苷酸前药化合物
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CA3189501A1 (en) 2020-08-31 2022-03-03 Emory University 5'-substituted nucleoside monophosphates, prodrugs thereof, and uses related thereto
WO2023177894A1 (en) 2022-03-18 2023-09-21 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and an antimetabolite agent
EP4382093B1 (en) 2022-12-05 2025-08-27 a Fine House S.A. Oral suspensions comprising capecitabine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1135258A (en) * 1979-06-15 1982-11-09 Richard D'souza Process for the preparation of 5'deoxy-5-fluorouridine
CA1264738A (en) * 1984-12-04 1990-01-23 Eli Lilly And Company Treatment of tumors in mammals
CA1327358C (en) * 1987-11-17 1994-03-01 Morio Fujiu Fluoro cytidine derivatives

Also Published As

Publication number Publication date
PL174100B1 (pl) 1998-06-30
BG98304A (bg) 1994-01-03
ES2086856T3 (es) 1996-07-01
DK0602454T3 (da) 1996-07-29
YU49411B (sh) 2006-01-16
RU2458932C2 (ru) 2012-08-20
FI935616A0 (fi) 1993-12-14
JP2501297B2 (ja) 1996-05-29
DE69302360T2 (de) 1996-10-31
LV10625B (en) 1996-04-20
NO934671D0 (no) 1993-12-17
AU5069093A (en) 1994-06-30
NO300066B1 (no) 1997-04-01
JPH06211891A (ja) 1994-08-02
FI112365B (fi) 2003-11-28
FI935616L (fi) 1994-06-19
SA93140409B1 (ar) 2004-07-24
SK281403B6 (sk) 2001-03-12
HU211965A9 (en) 1996-01-29
IS4108A (is) 1994-06-19
HRP931430B1 (en) 1999-08-31
GR3020286T3 (en) 1996-09-30
CZ273193A3 (en) 1994-07-13
TW372239B (en) 1999-10-21
EP0602454A1 (en) 1994-06-22
CN1094056A (zh) 1994-10-26
YU77993A (sh) 1996-10-18
CZ284788B6 (cs) 1999-03-17
RU2493162C1 (ru) 2013-09-20
LV10625A (lv) 1995-04-20
IL108000A0 (en) 1994-04-12
HRP931430A2 (en) 1998-06-30
EE03086B1 (et) 1998-04-15
ZA939293B (en) 1994-06-18
HU9303525D0 (en) 1994-04-28
PL301541A1 (en) 1994-06-27
NO934671L (no) 1994-06-20
MY109282A (en) 1996-12-31
LTIP1627A (en) 1994-07-15
EP0602454B1 (en) 1996-04-24
DE69302360D1 (de) 1996-05-30
LT3115B (en) 1994-12-27
SK144493A3 (en) 1994-10-05
CN1035617C (zh) 1997-08-13
SI9300648A (en) 1994-09-30
HK1005875A1 (en) 1999-01-29
BR9305089A (pt) 1994-07-05
BG61485B1 (bg) 1997-09-30
KR940014428A (ko) 1994-07-18
KR100347218B1 (ko) 2003-01-24
SI9300648B (sl) 2000-06-30
NZ250414A (en) 1995-12-21
ATE137244T1 (de) 1996-05-15
UA39158C2 (uk) 2001-06-15
CA2103324C (en) 1997-12-23
RU2135511C1 (ru) 1999-08-27
GEP20074251B (en) 2007-12-10
SV1993000080A (es) 1996-01-26
HU218291B (en) 2000-07-28
AU671491B2 (en) 1996-08-29
RO112619B1 (ro) 1997-11-28
US5472949A (en) 1995-12-05
HUT65757A (en) 1994-07-28
PH30168A (en) 1997-01-21
CA2103324A1 (en) 1994-06-19

Similar Documents

Publication Publication Date Title
UY23697A1 (es) Procedimiento para la preparacion de 5'-deoxi-5'-fluorcitidinas sustitutas del n-oxicarbonilo
MX173347B (es) Procedimiento para producir derivados de 5'-deoxi-5-fluorocitidina y producto obtenido
AU529001B2 (en) Addition of silicon-bonded hydrogen atoms to aliphatic multiple bands
ES480127A1 (es) Un procedimiento para la preparacion de tienamicina.
DE3567023D1 (en) Diphosphonic-acid derivatives, process for their preparation and medicines containing them
ES8703860A1 (es) Un procedimiento para preparar derivados de aminoalquilfenaxi.
CA1262357A (en) N-HYDROXYL PROTECTIVE GROUPS AND METHOD FOR THE PREPARATION OF 3-ACYLAMINO-1-HYDROXY-2-AZETIDINONES
HUT45512A (en) Process for producing anticancer quinazoline derivatives and pharmaceutics comprising the same
UY23635A1 (es) Procedimiento para la preparacion de conjugados del peg interferon
KR950704284A (ko) 칼슘 채널 길항제로서의 피페리딘 유도체(Piperidine Derivatives as Calcium Channel Antagonists)
ES2001094A6 (es) Un procedimiento para la preparacion de un derivado de guanina
CO4700291A1 (es) Compuestos quimicos
HUT48616A (en) Process for producing thienylethylamine derivatives
ES2059626T3 (es) Nuevos esteres de estramustina.
HUT46936A (en) Process for producing cyclooktaamilose
ES2072765T3 (es) Procedimiento para la obtencion de 5,6-dihidroxi-indolinas.
ES476385A1 (es) Un procedimiento para preparar derivados de transpirindina
CA2273989A1 (fr) Nouveaux derives d'histidine, procede de preparation et leur utilisation comme agents anti-radicaux libres
IL97105A0 (en) Indole derivatives,their preparation and pharmaceutical compositions containing them
AU539348B2 (en) 5,6,8,9-tetrahydro-7h-dibenz(d,f)azonine derivatives
FR2383177A1 (fr) Procede de preparation de derives de 2,1,3-thiadiazine-4-one-2,2-dioxyde
FR2446841A1 (fr) Procede de preparation de 1a,3b-dihydroxy-d5-steroides
ES450919A1 (es) Procedimiento para la preparacion de copolimeros conteniendoinsaturaciones dienicas conjugadas.
SE7702233L (sv) Forfarande for framstellning av en substituerad purin
EP0640613A4 (en) OLIGOSIALYL-1,2-DIALKYL-Sn-GLYCEROL AND INTERMEDIATE FOR ITS SYNTHESIS.

Legal Events

Date Code Title Description
VENC Patent expired

Effective date: 20131116